GUIDED THERAPEUTICS INC [GTHP] Filings

10-Q 1 gthp_10q.htm FORM 10-Q gthp_10q.htm

UNITED STATES SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934

For the quarterly period ended June 30, 2024

Commission File No. 000-22179

GUIDED THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		58-2029543
(State or other jurisdiction of incorporation or organization)		I.R.S. Employer Identification No.)

5835 Peachtree Corners East, Suite B

Peachtree Corners, Georgia 30092

(Address of principal executive offices) (Zip Code)

(770) 242-8723

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No☐

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

Large Accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13 (a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐ No ☒

As of August 10, 2024, the registrant had 56,550,370 shares of Common Stock, $0.001 par value per share, outstanding.

PART I — FINANCIAL INFORMATION
		Page
Item 1.	Financial Statements
	Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023	3
	Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023	5
	Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three and Six Months Ended June 30, 2024 and 2023	6
	Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023	10
	Notes to Unaudited Condensed Consolidated Financial Statements	11

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	36

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	43

Item 4.	Controls and Procedures	43

PART II — OTHER INFORMATION

Item 1.	Legal Proceedings	44

Item 1A.	Risk Factors	44

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44

Item 3.	Defaults Upon Senior Securities	44

Item 4.	Mine Safety Disclosures	44

Item 5.	Other Information	44

Item 6.	Exhibits	45

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)

	June 30,		December 31,
	2024		2023
ASSETS

Current Assets:
Cash and cash equivalents	$	275	$	591
Trade receivables, net of allowance for doubtful accounts of nil and $2 at June 30, 2024 and December 31, 2023, respectively.		2		7
Inventory, net of reserves of $818 at June 30, 2024 and December 31, 2023		632		632
Other current assets		112		163
Total current assets		1,021		1,393

Non-Current Assets:
Property and equipment, net		28		32
Operating lease right-of-use assets, net of amortization		185		227
Other assets		17		17
Total non-current assets		230		276

TOTAL ASSETS	$	1,251	$	1,669

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities:
Accounts payable	$	2,143	$	1,991
Accounts payable, related parties		34		32
Accrued liabilities		840		1,068
Deferred revenue		748		424
Current portion of lease liability		99		91
Current portion of long-term debt, related parties		520		39
Short-term notes payable		112		59
Short-term convertible debt		94		1,105
Short-term convertible debt in default		1,130		-
Derivative liability at fair value		12		-
Total current liabilities		5,732		4,809

Long-Term Liabilities
Long-term lease liability		104		155
Long-term notes payable		59		-
Long-term debt, related parties		23		511
Total long-term liabilities		186		666

Total liabilities		5,918		5,475

COMMITMENTS AND CONTINGENCIES (Note 6)

Table of Contents

STOCKHOLDERS’ DEFICIT:

Series C convertible preferred stock, $0.001 par value; 9.0 shares authorized, 0.3 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $286 at June 30, 2024 and December 31, 2023.		105			105
Series C1 convertible preferred stock, $0.001 par value; 20.3 shares authorized, 1.0 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $1,049 at June 30, 2024 and December 31, 2023.		170			170
Series C2 convertible preferred stock, $0.001 par value; 5,000 shares authorized, 2.7 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $2,700 at June 30, 2024 and December 31, 2023.		439			439
Series D convertible preferred stock, $0.001 par value; 6.0 shares authorized, 0.4 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $438 at June 30, 2024 and December 31, 2023.		159			159
Series E convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.9 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $883 at June 30, 2024 and December 31, 2023.		834			834
Series F convertible preferred stock, $0.001 par value; 1.5 shares authorized, 1.1 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $1,006 at June 30, 2024 and December 31, 2023.		838			838
Series F-2 convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.5 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $520 at June 30, 2024 and December 31, 2023.		475			475
Common stock, $0.001 par value; 500,000 shares authorized, 56,267 and 54,105 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively.		3,442			3,441
Additional paid-in capital		141,320			140,983
Treasury stock at cost		(132	)		(132	)
Accumulated deficit		(152,317	)		(151,118	)

Total stockholders’ deficit		(4,667	)		(3,806	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	1,251		$	1,669

The accompanying notes are an integral part of these condensed consolidated statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share data)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2024			2023			2024			2023

Sales - devices and disposables	$	-		$	44		$	6			66
Cost of goods sold		-			33			2			42
Gross profit		-			11			4			24

Operating expenses:
Research and development		222			66			275			73
Sales and marketing		69			61			142			134
General and administrative		364			1,389			600			2,166
Total operating expenses		655			1,516			1,017			2,373

Loss from operations		(655	)		(1,505	)		(1,013	)		(2,349	)

Other income (expenses):
Interest expense		(75	)		(69	)		(139	)		(134	)
Interest income		-			-			3			-
Change in fair value of derivative liability		(7	)		-			(7	)		5
Gain from extinguishment of debt		16			17			33			52
Other income (expenses)		12			-			12			-
Total other income (expense)		(54	)		(52	)		(98	)		(77	)

Loss before income taxes		(709	)		(1,557	)		(1,111	)		(2,426	)
Provision for income taxes		-			-			-			-

Net loss		(709	)		(1,557	)		(1,111	)		(2,426	)
Deemed dividend for warrant exchanges		-			-			-			(65	)
Preferred stock dividends		(49	)		(47	)		(88	)		(82	)

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(758	)	$	(1,604	)	$	(1,199	)	$	(2,573	)

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)
Diluted	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)

Weighted average shares outstanding
Basic		55,986			50,970			55,368			50,138
Diluted		55,986			50,970			55,368			50,138

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED JUNE 30, 2024
(unaudited, in thousands)

	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock
	Series C				Series C1				Series C2				Series D
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount
Balance at March 31, 2024		-	$	105		1	$	170		2	$	439		1	$	159
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-		-		-
Issuance of warrants with debt		-		-		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-		-		-
Net loss		-		-		-		-		-		-		-		-
Balance at June 30, 2024		-	$	105		1	$	170		2	$	439		1	$	159

	Preferred Stock				Preferred Stock				Preferred Stock
	Series E				Series F				Series F2
	Shares		Amount		Shares		Amount		Shares		Amount
Balance at March 31, 2024		1	$	834		1	$	838		-	$	475
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-
Issuance of warrants with debt		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-
Net loss		-		-		-		-		-		-
Balance at June 30, 2024		1	$	834		1	$	838		-	$	475

					Additional
	Common Stock				Paid-In		Treasury			Accumulated
	Shares		Amount		Capital		Stock			Deficit				Total
Balance at March 31, 2024		55,614	$	3,441	$	141,218	$	(132	)	$	(151,559	)	$	(4,012	)
Issuance of common stock for payment of Series D preferred dividends		71		-		6		-			-			6
Issuance of common stock for payment of Series F-2 preferred dividends		72		-		7		-			-			7
Issuance of common stock for payment of interest		510		1		47		-			-			48
Issuance of warrants with debt		-		-		12		-			-			12
Stock-based compensation		-		-		30		-			-			30
Accrued preferred dividends		-		-		-		-			(49	)		(49	)
Net loss		-		-		-		-			(709	)		(709	)
Balance at June 30, 2024		56,267	$	3,442	$	141,320	$	(132	)	$	(152,317	)	$	(4,667	)

The accompanying notes are an integral part of these condensed consolidated statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED JUNE 30, 2023
(unaudited, in thousands)

	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock
	Series C				Series C1				Series C2				Series D
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount
Balance at March 31, 2023		-	$	105		1	$	170		2	$	439		1	$	159
Common stock warrants exercised		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-		-		-
Conversion of Series F preferred stock to common stock		-		-		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-		-		-
Net loss		-		-		-		-		-		-		-		-
Balance at June 30, 2023		-	$	105		1	$	170		2	$	439		1	$	159

	Preferred Stock				Preferred Stock					Preferred Stock
	Series E				Series F					Series F2
	Shares		Amount		Shares		Amount			Shares		Amount
Balance at March 31, 2023		1	$	834		1	$	858			3	$	475
Common stock warrants exercised		-		-		-		-			-		-
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-			-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-			-		-
Conversion of Series F preferred stock to common stock		-		-		-		(20	)		-		-
Stock-based compensation		-		-		-		-			-		-
Accrued preferred dividends		-		-		-		-			-		-
Net loss		-		-		-		-			-		-
Balance at June 30, 2023		1	$	834		1	$	838			3	$	475

					Additional
	Common Stock				Paid-In			Treasury			Accumulated
	Shares		Amount		Capital			Stock			Deficit			Total
Balance at March 31, 2023		50,814	$	3,438	$	139,127		$	(132	)	$	(148,328	)	$	(2,855	)
Common stock warrants exercised		48		-		9			-			-			9
Issuance of common stock for payment of Series D preferred dividends		33		-		8			-			-			8
Issuance of common stock for payment of Series F-2 preferred dividends		36		-		9			-			-			9
Conversion of Series F preferred stock to common stock		80		-		20			-			-			-
Stock-based compensation		-		-		1,119			-			-			1,119
Accrued preferred dividends		-		-		(1	)		-			(47	)		(48	)
Net loss		-		-		-			-			(1,557	)		(1,557	)
Balance at June 30, 2023		51,011	$	3,438	$	140,291		$	(132	)	$	(149,932	)	$	(3,315	)

The accompanying notes are an integral part of these condensed consolidated statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE SIX MONTHS ENDED JUNE 30, 2024
(unaudited, in thousands)

	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock
	Series C				Series C1				Series C2				Series D
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount
Balance at December 31, 2023		-	$	105		1	$	170		2	$	439		1	$	159
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series E preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-		-		-
Settlement of previously accrued professional fees through common stock issuance		-		-		-		-		-		-		-		-
Issuance of warrants with debt		-		-		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-		-		-
Net loss		-		-		-		-		-		-		-		-
Balance at June 30, 2024		-	$	105		1	$	170		2	$	439		1	$	159

	Preferred Stock				Preferred Stock				Preferred Stock
	Series E				Series F				Series F2
	Shares		Amount		Shares		Amount		Shares		Amount
Balance at December 31, 2023		1	$	834		1	$	838		-	$	475
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of Series E preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of Series F preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-
Settlement of previously accrued professional fees through common stock issuance		-		-		-		-		-		-
Issuance of warrants with debt		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-
Net loss		-		-		-		-		-		-
Balance at June 30, 2024		1	$	834		1	$	838		-	$	475

					Additional
	Common Stock				Paid-In		Treasury			Accumulated
	Shares		Amount		Capital		Stock			Deficit			Total
Balance at December 31, 2023		54,105	$	3,441	$	140,983	$	(132	)	$	(151,118	)	$	(3,806	)
Issuance of common stock for payment of Series D preferred dividends		125		-		15		-			-			15
Issuance of common stock for payment of Series E preferred dividends		52		-		8		-			-			8
Issuance of common stock for payment of Series F preferred dividends		445		-		54		-			-			54
Issuance of common stock for payment of Series F-2 preferred dividends		236		-		27		-			-			27
Issuance of common stock for payment of interest		904		1		104		-			-			105
Settlement of previously accrued professional fees through common stock issuance		400		-		57		-			-			57
Issuance of warrants with debt		-		-		12		-			-			12
Stock-based compensation		-		-		60		-			-			60
Accrued preferred dividends		-		-		-		-			(88	)		(88	)
Net loss		-		-		-		-			(1,111	)		(1,111	)
Balance at June 30, 2024		56,267	$	3,442	$	141,320	$	(132	)	$	(152,317	)	$	(4,667	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE SIX MONTHS ENDED JUNE 30, 2023
(unaudited, in thousands)

	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock
	Series C				Series C1				Series C2				Series D
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount
Balance at December 31, 2022		-	$	105		1	$	170		2	$	439		1	$	159
Common stock warrants exercised		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series E preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-		-		-
Conversion of Series E preferred stock to common stock		-		-		-		-		-		-		-		-
Conversion of Series F preferred stock to common stock		-		-		-		-		-		-		-		-
Conversion of Series F-2 preferred stock to common stock		-		-		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-		-		-
Impact of warrant exchanges		-		-		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-		-		-
Net loss		-		-		-		-		-		-		-		-
Balance at June 30, 2023		-	$	105		1	$	170		2	$	439		1	$	159

	Preferred Stock					Preferred Stock					Preferred Stock
	Series E					Series F					Series F2
	Shares		Amount			Shares		Amount			Shares		Amount
Balance at December 31, 2022		1	$	839			1	$	880			3	$	489
Common stock warrants exercised		-		-			-		-			-		-
Issuance of common stock for payment of Series D preferred dividends		-		-			-		-			-		-
Issuance of common stock for payment of Series E preferred dividends		-		-			-		-			-		-
Issuance of common stock for payment of Series F preferred dividends		-		-			-		-			-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-			-		-			-		-
Conversion of Series E preferred stock to common stock		-		(5	)		-		-			-		-
Conversion of Series F preferred stock to common stock		-		-			-		(42	)		-		-
Conversion of Series F-2 preferred stock to common stock		-		-			-		-			-		(14	)
Issuance of common stock for payment of interest		-		-			-		-			-		-
Stock-based compensation		-		-			-		-			-		-
Impact of warrant exchanges		-		-			-		-			-		-
Accrued preferred dividends		-		-			-		-			-		-
Net loss		-		-			-		-			-		-
Balance at June 30, 2023		1	$	834			1	$	838			3	$	475

					Additional
	Common Stock				Paid-In			Treasury			Accumulated
	Shares		Amount		Capital			Stock			Deficit			Total
Balance at December 31, 2022		48,596	$	3,437	$	138,090		$	(132	)	$	(147,359	)	$	(2,883	)
Common stock warrants exercised		1,120		1		230			-			-			231
Issuance of common stock for payment of Series D preferred dividends		59		-		14			-			-			14
Issuance of common stock for payment of Series E preferred dividends		26		-		8			-			-			8
Issuance of common stock for payment of Series F preferred dividends		233		-		53			-			-			53
Issuance of common stock for payment of Series F-2 preferred dividends		121		-		29			-			-			29
Conversion of Series E preferred stock to common stock		20		-		5			-			-			-
Conversion of Series F preferred stock to common stock		200		-		42			-			-			-
Conversion of Series F-2 preferred stock to common stock		60		-		14			-			-			-
Issuance of common stock for payment of interest		178		-		59			-			-			59
Stock-based compensation		400		-		1,683			-			-			1,683
Impact of warrant exchanges		-		-		65			-			(65	)		-
Accrued preferred dividends		-		-		(1	)		-			(82	)		(83	)
Net loss		-		-		-			-			(2,426	)		(2,426	)
Balance at June 30, 2023		51,011	$	3,438	$	140,291		$	(132	)	$	(149,932	)	$	(3,315	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

GUIDED THERAPEUTICS INC [GTHP] Filings
10-Q	[2024-08-14]
10-Q	[2024-05-14]
10-K	[2024-03-28]
10-Q	[2023-11-13]
10-Q	[2023-08-10]
10-Q	[2023-05-15]
10-K	[2023-03-30]
S-1	[2023-01-13]
10-Q	[2022-11-14]
10-Q	[2022-08-15]
10-Q	[2022-05-16]
10-K	[2022-03-30]
10-Q	[2021-11-15]
S-1	[2021-09-29]
10-Q	[2021-08-18]
10-Q	[2021-05-21]
10-K	[2021-04-07]
10-Q	[2020-11-05]
S-1	[2020-09-10]
10-Q	[2020-08-20]
10-Q	[2020-07-07]
10-K	[2020-04-20]
10-Q	[2020-03-09]
10-Q	[2020-02-11]
10-Q	[2019-07-11]
10-K	[2019-05-08]
10-Q	[2018-11-14]
10-Q	[2018-08-14]
S-1	[2018-06-14]
10-Q	[2018-05-21]
10-K	[2018-04-17]
10-Q	[2017-11-20]
10-Q	[2017-08-18]
10-Q	[2017-05-22]
10-K	[2017-03-22]
10-Q	[2016-12-05]
10-Q	[2016-08-17]
S-1	[2016-07-01]
10-Q	[2016-05-19]
S-1	[2016-03-24]
10-K	[2016-03-15]
10-Q	[2015-11-12]
S-1	[2015-09-30]
10-Q	[2015-08-13]
S-1	[2015-07-15]
10-Q	[2015-05-13]
S-1	[2015-04-23]
10-K	[2015-03-25]
10-Q	[2014-11-12]
S-1	[2014-09-15]
10-Q	[2014-08-13]
10-Q	[2014-05-15]
S-1	[2014-04-30]
10-K	[2014-03-26]
10-Q	[2013-11-13]
10-Q	[2013-08-14]
S-1	[2013-07-05]
10-Q	[2013-05-14]
10-K	[2013-03-27]
S-1	[2012-11-14]
10-Q	[2012-11-13]
10-Q	[2012-08-14]
10-Q	[2012-05-14]
10-K	[2012-03-28]